Management of Psychosis in Parkinson’s Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition

Raquel N. Taddei, Seyda Cankaya, Sandeep Dhaliwal, and K. Ray Chaudhuri

Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College Hospital, London, UK

Correspondence should be addressed to Raquel N. Taddei; raqueltaddei@hotmail.com

Received 26 May 2017; Accepted 6 August 2017; Published 12 September 2017

1. Introduction

Nonmotor symptoms have an important impact on quality of life in PD patients and their caregivers and are largely recognized as such by a growing number of health care providers [1, 2]. Psychosis is recognized as one of the most frequent and disabling nonmotor symptoms in PD with prevalences of 20% up to 70% in advanced stages of the condition [3]. Its relevance is such that it has even been named as the main feature of one of the seven proposed nonmotor subtypes of PD described by Sauerbier et al. [4]. In this review we aim at providing an up to date practical approach to psychosis in PD, with especial emphasis on clinical subtypes and pathophysiological mechanisms underlying this condition with the aim of leading to better intervention strategies in the nearer future.

2. Defining PD Psychosis

2.1. History. The history of psychosis in PD goes back to the early 19th century, where the presence of mental disturbances among PD patients was described as being rare and was accounted for as either a consequence of a chronic disease evolution or regarded as coincidental [5]. After an outbreak of encephalitis lethargica between 1915 and 1926, a condition of unknown origin with acute onset and often chronic persistence of various neurological symptoms, including headache, lethargy, catatonia, parkinsonism, and tremor, a potential link between an altered mental state and parkinsonism was proposed and the first idea of complex psychotic symptoms in postencephalitic parkinsonism (PEP) cases was described [6, 7]. In more recent years however, the etiologic relationship between the encephalitis outbreak and the
Box 1: The ICD-10 classification of mental and behavioural disorders: definition criteria for acute and transient psychosis. F23, F30, F32: diagnosis codes of psychotic (F23) and mood disorders (F30 and F32) taken from ICD-10 guidelines; reference: taken from WHO International classifications, ICD-10 guidelines [15].
Parkinson's Disease

(A) Characteristic symptoms
Presence of at least one of the following symptoms (specify which of the symptoms fulfill the criteria)
(i) Illusions
(ii) False sense of presence
(iii) Hallucinations
(iv) Delusions
(B) Primary diagnosis
UK brain bank criteria for PD
(C) Chronology of the onset of symptoms of psychosis
The symptoms in Criterion (A) occur after the onset of PD
(D) Duration
The symptom(s) in Criterion (A) are recurrent or continuous for 1 month
(E) Exclusion of other causes
The symptoms in Criterion (A) are not better accounted for by another cause of Parkinsonism such as dementia with Lewy bodies, psychiatric disorders such as schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features, or a general medical condition including delirium
(F) Associated features (specify if associated)
(i) With/without insight
(ii) With/without dementia
(iii) With/without treatment for PD (specify drug, surgical, other)

Box 2: Proposed criteria for psychosis in Parkinson's disease. PD, Parkinson's disease; UK, United Kingdom; references: Ravina et al., 2007, and Fenelon et al., 2008 [22, 23].

The prevalence of PD psychosis varies widely; among untreated PD patients it is reported to occur “rarely” [24], whereas in treated patients prevalence widely differs in the literature, with reported illusions or hallucinations occurring in 15–40% of treated PD patients [25] and an estimated development of psychosis in up to 60% of PD patients after a 12-year disease duration [26] or even 70% in “advanced” PD stages [3]. The occurrence of minor phenomena is reported to range between 17% and 72% in the current literature [27–30].

A recently published study on 423 drug-naive PD patients followed up for 3–4 years showed an overall prevalence of psychotic symptoms in 27% of the PD patients after a median time of 19 months [19]. Table 1 shows the different prevalence rates of PD psychosis reported among various studies.

Various risk factors have been linked with the development of PD psychosis, such as the use of dopaminergic drugs as one of the first described ones. A recent study by the Parkinson's Progression Markers Initiative (PPMS) found that there were no significant differences with regard to occurrence of PD psychosis after starting L-Dopa or dopamine agonists, but a higher proportion of PD psychosis was observed over time after a period of 24 months in PD patients treated with dopamine agonists compared to the ones treated with L-Dopa [19].

Nowadays, emphasis on various other related factors has been attributed to leading to psychosis in PD patients, including higher age, later disease onset, higher PD severity (H&Y state), longer PD duration [27, 32], hyposmia [33], cognitive impairment, depression [34], diurnal somnolence, REM sleep behaviour disorder [28], visual disorders, severe axial impairment, autonomic dysfunction, and high medical comorbidity and polypharmacy, especially including the use of psychoactive drugs [3, 23, 35].

To assess the risk of developing psychosis, several scales are accessible either to address the presence of psychosis or to establish its severity. These include the PD nonmotor symptom scale developed by Chaudhuri et al. [36] and subscores of the MDS-UPDRS scale [37], as well as more specific scales directed towards assessing specifically psychiatric comorbidity in PD, including the Parkinson Psychosis Questionnaire [38], the Scale for Assessment of Positive Symptoms [39], and the Scale for Evaluation of Neuropsychiatric Disorders in PD [40]. These available scales are summarised in Table 2.

2.3. Other Psychotic Syndromes. In the following section, we will revise three specific subtypes of psychosis that may cooccur or contribute to the “classical” PD psychosis described above, in order to provide a complete revision on this topic.

2.3.1. Charles-Bonnet Syndrome. This syndrome with an estimated prevalence of 0.4% up to 30% in the overall population [41–45] dates back to a Swiss scientist named Charles-Bonnet, who described the occurrence of detailed visual hallucinations including figures, persons, and animals in his visually impaired grandfather, after losing his sight due to a bilateral cataract surgery. But it was not until 1967 that another Swiss scientist called G. de Morsier described this syndrome with the currently used term Charles-Bonnet syndrome. Diagnostic criteria for this syndrome are yet a topic of controversy, the current definition being the presence of visual hallucinations occurring as a result of ocular or visual pathway disease. The visual hallucinations can be of simple or complex nature, including hallucinations of faces or people-like figures [46], and normally last for seconds to a few hours. Most patients do not describe a negative or fearful experience during their visual hallucinations [41] and partial or full insight of
| Study                              | N  | Setting/design                  | Assessment instruments                  | Main findings                                                                 |
|-----------------------------------|----|---------------------------------|----------------------------------------|-------------------------------------------------------------------------------|
| Celesia et al., 1970              | 45 | Outpatient/prospective longitudinal | Columbia disability scale              | 17% developed psychosis (delusions, hallucinations, behavioral disorder)        |
| Sweet et al., 1976                | 100| Outpatient/retrospective        | Cornell, weighted scale, WAIS           | 60% agitated confusion                                                        |
| Moskovitz et al., 1978            | 88 | Outpatient/retrospective        | No                                     | 48% experienced vivid dreams (30.7%), hallucinations (29.5%), illusions (5.7%), nonconfusional (9.1%), confusional psychoses (3.4%) |
| de Smet et al., 1982              | 75 | Inpatient/retrospective         | No                                     | 31% confusional states                                                        |
| Tanner et al., 1983               | 775| Outpatient/retrospective        | HY                                     | 33% hallucinations                                                            |
| Fischer et al., 1990              | 25 | Inpatient/retrospective         | HY, MMSE                               | 80% at least one episode of "pharmacotoxic psychosis"                          |
| Sanchez-Ramos et al., 1996        | 214| Outpatient/prospective cross-sectional | HY, MMSE                              | 25.7% visual hallucinations                                                  |
| Inzelberg et al., 1998            | 121| Outpatient/prospective cross-sectional | HY, SMT                               | 29% visual, 8% visual and auditory hallucinations                             |
| Aarsland et al., 1999             | 245| Community/prospective cross-sectional | UPDRS, MMSE, DSM-III-R, MADRAS         | 25.5% vivid dreaming, 9.8% hallucinations with insight retained, and 6% severe hallucinations or delusions |
| Fenelon et al., 2000              | 216| Outpatient/prospective cross-sectional | UPDRS, HY, MMP, CES-D, DSM-IV         | 39.8% hallucinations. Minor hallucinations 25.5%, formed visual hallucinations 22.2%, and auditory hallucinations 9.7% |
| Giladi et al., 2000               | 172| Outpatient/prospective cross-sectional | HY, MMSE, DSM-IV, ADAS-cog          | 27% had psychosis                                                             |
| Goetz et al., 2001                | 60 | Outpatient/prospective longitudinal | UPDRS, HY, RHI                       | Hallucinations increased from 33% at baseline to 44% at 18 months and 63% at 48 months |
| Holroyd et al., 2001              | 102| Outpatient/prospective cross-sectional | DSM-IV, TICS, GDS                    | 29.4% had hallucinations or delusions                                           |
| DOE De Maindreille, 2004          |    |                                  |                                        | Hallucinations increased from 41.7% to 49.6% over 12 months                   |

HY: Hoehn and Yahr staging; SMT: Short Mental Test; MMSE: Mini Mental State Examination; UPDRS: Unified PD Rating Scale; MMP: Mini Mental Parkinson; DSM-III-R: Diagnostic and Statistical Manual for Psychiatric Disorders, revised third edition; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edition; MADRAS: Montgomery and Asberg Depression Rating Scale; RHI: Rush Hallucination Inventory; ADAS-cog: Alzheimer’s Disease Assessment Scale (ADAS) Cognitive Section; TICS: Telephone Interview for Cognitive Status; GDS: Geriatric Depression Scale; WAIS: Wechsler Adult Intelligence Scale; CES-D: Center for Epidemiologic Studies-Depression self-rating scale; reference: Papapetropoulos and Mash, 2005 [31].
2.3.2. "Malignant": DLB/PD Dementia with Psychosis. De-

teria with Lewy bodies (DLB) and PD associated dementia (PDD) are two separate entities, yet both involving a sim-
ilar pathological pathway of deposition of Alpha-synuclein within the brain in form of Lewy bodies. Presence of hallucinations is a common hallmark in both entities, being described in as many as 25–30% of DLB and PDD patients [22] and being most commonly of visual character, although also acoustic and haptic (tactile) hallucinations can occur [46]. In the progress of more severe presence of cognitive decline, visual hallucinations tend to shift from a blurred character among PD and PDD patients to fully formed complex visual hallucinations among DLB patients [46]. The distinction between both types of dementia is nonetheless a challenge and often complicated by an overlap of the clinical presentations and an unclear time window. DLB is commonly diagnosed, when cognitive impairment occurs within a year of development of parkinsonian symptoms, whereas PDD is defined as dementia occurring at least 1 year after motor symptom onset [50]. A recent study by Fritz et al. could additionally find some clinical features that differ between DLB and PD which included a slower speed, shorter stride length, and increased stance phases of gait as well as a higher frequency of falls among DLB when compared to PD patients [51]. The differentiation and correct recognition thus pose a challenge to the clinician.

With regard to the presence of hallucinations, in DLB these tend to occur early in the disease course and are not associated with dopaminergic medication, whereas in PDD they tend to develop in later stages and to be related to intake of dopaminergic therapy, mostly of dopamine agonists [52]. Autopsy series in DLB with hallucinations showed a deposition of Lewy bodies in the inferior temporal cortex, with similar anatomical correlates found in autopsies of PD patients with hallucinations, so that hallucinations were correlated with the presence of Lewy body pathology in the temporal lobes [53]. Nonetheless, a more recent study assessing structural changes in dementia by means of MRI scans could correlate the presence of hallucinations with a cortical atrophy in visual pathways, rather than an anatomical corre-
late in temporal regions [54]. As a potential further biomarker of hallucinations in PDD, a study on the effect of fluctuating cognition in DLB and PDD showed a significantly higher prevalence of hallucinations among DLB and PDD patients when fluctuating cognition features were present [55].

### Table 2: Recommended scales for the assessment of psychosis in Parkinson’s disease.

| Scale                                      | Objective                                                                 | References                          |
|--------------------------------------------|---------------------------------------------------------------------------|-------------------------------------|
| PD nonmotor symptom scale                  | Risk of developing psychosis                                              | Chaudhuri et al., 2007              |
| MDS-UPDRS I, item 1.2                      | Presence and severity of psychosis                                         | Goetz et al., 2007                  |
| Parkinson Psychosis Questionnaire (PPQ)   | Presence and severity of psychosis                                         | Sawada and Oeda, 2013               |
| Scale for Evaluation of Neuropsychiatric Disorders in Parkinson’s disease (SEND-PD) | Presence, severity of psychosis, and other neuropsychiatric symptoms       | Rodriguez-Violante et al., 2014     |
| Scale for Assessment of Positive Symptoms (SAPS) | Presence, severity, and impact of psychosis                             | Voss et al., 2013                   |

PD, Parkinson’s disease; MDS-UPDRS I: Movement Disorder Society Unified Parkinson’s Disease Rating Scale I; SEND-PD: Scale for Evaluation of Neuropsychiatric Disorders in Parkinson’s disease; SAPS: Scale for Assessment of Positive Symptoms; reference: Levin et al., 2016 [3].
Table 3: Features of delirium versus psychosis in PD.

| Features                  | Delirium                                      | Psychosis                                      |
|---------------------------|-----------------------------------------------|------------------------------------------------|
| Onset                     | Acute                                         | Insidious                                      |
| Course                    | Fluctuating, usually resolving over days to weeks | Progressive                                    |
| Conscious level           | Often impaired; can fluctuate rapidly; can be drowsy or hyperaroused | Clear                                          |
| Cognitive defects         | Poor short-term memory, poor attention span    | Subtle                                         |
| Hallucinations            | Common, especially visual                      | Common especially complex visual or auditory    |
| Key symptoms              | Inattention, thought disorganisation, day-night reversal | Hallucinations, delusions, thought insertion, withdrawal or broadcast, passivity phenomena, phantom boarder |
| Medical status            | Abnormal                                       | Normal                                         |

Reference: Vardy et al., 2015 [58].

3. Pathophysiology and Potential Biomarkers of Psychosis in PD

3.1. Introduction. Psychosis in PD patients is mostly arising in patients with a clear sensorium in a chronic setting after a long disease duration and is triggered or enhanced by pharmacological factors. Nonetheless, other recent risk factors have been studied, giving rise to a potential multifactorial underlying aetiology and thus physiopathology. The differentiation between early and late onset psychosis in general, and also specifically in PD, is not currently validated, having some studies randomly set cut-off values at 2–4 years of PD onset to determine early versus late onset psychosis [71]. More interestingly, the assessment of psychosis as a potential prodromal feature could give rise to finding biomarkers in PD, in order to predict its occurrence and treat it at early stages. In this section we will review the pathophysiology of psychosis, focusing on prodromal/premotor psychosis and on psychosis arising in the course of PD (with no differentiation between early and late onset), and then address potential biomarkers of PD psychosis.

3.2. Premotor versus Late Occurring PD Psychosis. To our knowledge only one study has been performed and recently published to analyze the presence of psychotic symptoms as a feature of the premotor state of PD; Pagonabarraga et al. studied a cohort of 50 drug-naïve PD patients and compared them with 100 healthy controls to assess the presence of hallucinations [72]. They found an overall prevalence of minor hallucinations in the untreated PD group of 42%, the onset of these being 7 months to 8 years prior to motor symptom onset. The prevalence of hallucinations in the control group was 5%. When comparing the cohort of PD patients and healthy controls, the groups did not differ in baseline characteristics, apart from a significant impairment in global cognitive function in the PD group compared with the control group. Nonetheless, dementia criteria were not met in any of the subjects included in the study. When then comparing the PD patients with and without hallucinations, older age and the presence of rapid-eye-movement behaviour disorder
(RBD) were statistically significantly correlated ($P < 0.05$) as seen in Table 4. This preliminary study sheds light on a potential prodromal occurrence of PD psychosis and proposes risk factors that could help recognize at-risk PD patients. Further studies with wider sample sizes are nonetheless needed.

As mentioned previously, the prevalence of psychosis in the course of PD varies widely in the literature. Psychosis itself represents a relevant burden in PD, involving their caregivers and health professionals, since it has been associated with a higher morbidity and mortality [73]. Additionally, together with depression and dementia, it poses one of the most prevalent nonmotor features in PD [74], accounting for up to one-fifth of the complications arising over time [75].

As to potential biomarkers, a strong correlation of psychosis with depression and REM behaviour disorders has been described by Lee and Weintraub in a study on 191 nondemented PD patients [74], where the risk of developing psychosis with comorbid depression and sleep related disorders was 5 times higher. In this study they identified an overall prevalence for psychotic symptoms in 21% of PD patients. The variables associated with the occurrence of psychosis were similar to previous studies, Hoehn and Yahr (H&Y) stage, disease duration, Unified PD Rating Scale (UPDRS) motor score, depression, anxiety, RBD symptoms, daytime sleepiness, and apathy. A nonstatistically significant trend towards psychosis under higher L-Dopa dosages was found, but no correlation with dopamine agonist therapy could be established, in contrast to previous studies. A lower Mini Mental State Examination (MMSE) score also indicated a trend towards psychosis.

The risk factors of psychosis thus seem to be related to multiple pathways involving different neurotransmitter systems, complicating the understanding of the underlying processes taking place.

### 3.3. Pathophysiology of PD Psychosis

The pathophysiological processes underlying PD psychosis can be subdivided into intrinsic (neurotransmitter-dysfunction related and thus not externally induced) and extrinsic (drug-related and thus a direct result of the use of pharmacological agents). While intrinsic PD psychosis is thought to be caused by alterations in dopamine, serotonin, and acetylcholine systems involving subcortical projections as well as synaptic and neuronal changes in limbic and cortical structures [76], extrinsic PD mainly involves dopaminergic or anticholinergic therapies, especially dopamine agonists [35, 72].

To better understand the neurotransmitter dysfunctions underlying the development of hallucinations, the effect of hallucinogenic agents with known mechanisms of actions is of advantage. Classically, hallucinogenic agents were subdivided into those affecting the cholinergic system and those involving the aminergic system, herein dopaminergic and serotoninergic agents being included [77]. The described clinical characteristics and associated hallucinations caused by these two distinct systems also differ: while the effects caused by anticholinergic agents are associated with peripheral autonomic features, confusion, disorientation, and visual hallucinations, mostly poorly formed and of a threatening nature, the symptoms caused by aminergic agents are characterised by a heightened awareness of objects, forms, and colours with a clear sensorium, sometimes involving the presence of hypnagogic phenomena of a dream-like quality [77].

A novel model to clarify the underlying mechanism of psychosis in PD proposed by Wolters [78] suggests that the DA stimulated orbitofrontal output activates dorsal raphe neurons, which release serotonin and activate 5HT2a receptors. These receptors stimulate GABAergic neurons which influence dopamine neurons in the ventral tegmental area [79] through the neurotransmitter glutamate. Finally

---

**Table 4: Clinical and demographic features of PD patients with and PD patients without hallucinations after following up prospectively.**

|                          | PD-mH ($n = 21$) | PD-NH ($n = 29$) | $P$   |
|--------------------------|------------------|------------------|-------|
| Age, y                   | 71.1 ± 7         | 65.8 ± 12        | 0.06 (t-test) |
| Education, y             | 8.4 ± 4          | 9.4 ± 5          | 0.45 (t-test) |
| Sex, $\delta$           | 57.10%           | 55.60%           | 0.91 ($\chi^2$) |
| Disease duration, months from onset of motor symptoms | 22.8 ± 10        | 28.8 ± 14        | 0.12 (t-test) |
| UPDRS-III, at baseline   | 18.3 ± 9         | 20.1 ± 8         | 0.47 (t-test) |
| Hoehn & Yahr, at baseline| 1.9 ± 0.2        | 2.1 ± 0.5        | 0.19 (t-test) |
| Predominance of motor symptoms, right% | 52.3             | 65.5             | 0.23 ($\chi^2$) |
| Depression, %            | 52.3             | 41.40%           | 0.39 ($\chi^2$) |
| Anxiety, %               | 47.6             | 48.2             | 0.91 ($\chi^2$) |
| Apathy, %                | 42.8             | 55.1             | 0.47 ($\chi^2$) |
| Insomnia, %              | 38.1             | 41.3             | 0.68 ($\chi^2$) |
| Daytime sleepiness, %    | 38.1             | 27.5             | 0.45 ($\chi^2$) |
| RBD, %                   | 38.1             | 10.3             | 0.03 ($\chi^2$) |
| Hyposmia, %              | 33.3             | 27.5             | 0.80 ($\chi^2$) |

PD-mH: Parkinson’s disease with minor hallucinations; PD-NH: PD without hallucinations; UPDRS-III: Unified PD Rating Scale, motor section; RBD: REM sleep behaviour disorder; reference: Pagonabarraga et al., 2016 [72].
excitation of the limbic system and inhibition of the prefrontal cortex take place, giving rise to an impaired selection and weighing of external environmental stimuli, thus leading to a mis/overinterpretation of external inputs.

Other hypotheses come from a combination of neurotransmitters from Birkmayer and Riederer [80], shedding light on a dopamine-serotonin imbalance as an underlying mechanism of psychosis. This goes along postmortem studies, which found a loss of serotonin among PD patients [81] and the evidence on the positive effect of pharmacological agents which act by activating the 5-HT2 receptors, such as pimavanserin.

Since cholinergic deficiency is present not only in Alzheimer's disease, but also in PDD and DLB [82], and there is a close link between cognitive impairment and psychosis, a potential implication of this neurotransmitter could be considered. This led to a further hypothesis on the pathophysiology of psychosis by Perry et al., who proposes a cholinergic-serotonergic imbalance [83, 84]. Cholinergic depletion is already regarded as a potential underlying cause of psychosis in DLB alongside visuospatial processing deficits, which could therefore be thought of having a similar mechanism in PD psychosis.

Papapetropoulos and Mash propose, based on the above-mentioned findings, a neurochemical pathway for PD psychosis pathogenesis [31], with a disruption in mesolimbic dopaminergic pathways that lead to a supersensitivity of the implicated DA neurons in the striatum along with facilitating systems involving the serotonergic/dopaminergic and serotoninergic/cholinergic balance as seen in Figure 1. Other factors, such as genetic variances or environmental factors, were also postulated in this study; studies on potential DA receptor genes variants implicated in hallucinations in PD have nonetheless shown controversial results, 2 studies suggesting an influence on psychosis by some genes [85, 86], but one other study not being conclusive on this relationship [87].

It is well known that treatment with antiparkinsonian drugs may induce psychotic features in PD patients, posing a limitation in their application and even leading to their discontinuation if severe symptoms arise. Dopamine replacement therapy is the current mainstay treatment of PD but its pulsatile administration leads to an increase in both tonic and phasic dopamine signalling [88, 89]. While the externally administered replacement of dopamine in areas of dopaminergic cell loss is of beneficial effect, the stimulation of relatively unaffected areas such as the ventral tegmental area and the ventral striatum can impair the functioning of these areas.

In a study conducted on PD patients with marked hallucinations under antiparkinsonian treatment, a clear sensorium even after long-term anticholinergic treatment and a precipitation of psychosis after increases of dopaminergic or anticholinergic drugs with a typically similar appearance of hallucinations within each patient could be found, whereas decreases in the dosage of dopaminergic or anticholinergic treatment showed to improve hallucinations [90]. These findings support a pathophysiological mechanism directly related to changes in both dopamine and acetylcholine levels within the brain related to externally administered medication.

Animal models on the effect of long-term L-Dopa therapy have also shown changes at dopamine receptor sites along behavioural changes. Particularly mesolimbic areas, with a known high density of dopaminergic and cholinergic nerve terminals, have been implicated in the pathophysiology of these underlying neuronal changes [90]. Furthermore, animal studies on MPTP-treated monkeys showed upregulations of D1 and D2 receptors in the denervated striatum [91], which could be replicated in humans in further studies, showing a potential compensatory upregulation of DA receptors presumably due to nigrostriatal DA denervation (so-called denervation supersensitivity) [92, 93].

Interestingly, abnormal dopaminergic transmission has also been observed in schizophrenia and schizotypal traits and has been considered a main characteristic of its underlying pathophysiology [94]. In PD patients receiving dopaminergic therapy, some positive schizotypal traits could be found, postulating a potentially, at least partially common pathway of psychosis development [95, 96]. Externally administered dopamine therapy is thought to stimulate supersensitive striatal and mesolimbic dopamine receptors thus leading to the generation of visual hallucinations, the connections to frontal regions being specifically implicated and thus an anatomically/topologically comprehensive pathway for the induction of PD psychosis [77]. Nonetheless, a small study on intravenous L-Dopa infusions in 5 nondemented PD patients with daily hallucinations did not trigger visual hallucinations, postulating that high levels of L-Dopa and thus DA receptor activation alone do not cause visual hallucinations solely, so that more complex systems might be involved [97].

The link between cognitive impairment and PD psychosis has been thoroughly described in the literature [74, 98] with a recent review stating a correlation of PD psychosis in patients with impairment in mainly cognitive executive, attentional, and visuospatial domains [98]. Further, PD psychosis has also been described as a risk factor for the development of PD dementia [32, 74], giving rise to a potential link between both complications. Accordingly, a recent study by Factor et al. [99] confirmed an association between hallucinations in PD and global cognitive decline but also described for the first time a lack of correlation between delusions and cognition in PD patients. Structural neuroimaging studies have shown evidence of pronounced atrophies in frontal and limbic areas, as well as in the visual pathways and cortex in PD patients with hallucinations and cognitive impairment [100], although some controversy within the results has also been reported [101]. With regard to neurotransmitter systems implied in the pathophysiology of both conditions, cholinergic and dopaminergic pathways are thought to be involved [102]. Evidence in favour of an underlying cholinergic degeneration in PD psychosis among cognitively impaired patients has been supported by the fact that choline acetyl transferase reduction has been found in the neocortex of hallucinating PD as well as Lewy body dementia patients [103, 104] and the fact that cholinesterase inhibitors improve psychotic symptoms in some cases of Lewy body dementia patients [105, 106]. With regard to the dopaminergic system, the finding of a missing relation between delusions and cognitive decline [107, 108], the reported cases were found to be described
in PD patients on dopamine agonists and the symptoms as reversible after dopaminergic drug discontinuation, shedding light on a direct and strong involvement of the dopaminergic pathways in the development of psychotic features defined as delusions. The complexity and controversy among clinical presentations, imaging findings, and neurotransmitter imbalance thought to be involved [18] have been recently addressed in a thorough review and have shed light on the need of future research into this field.

3.4. Potential Biomarkers of PD Psychosis. A biomarker is defined as a characteristic that can be objectively measured and that can indicate a normal biological process, a pathogenic process, or a pharmacologic response to a specific therapy [109]. Biomarkers can range from clinical, neuroimaging, and biochemical to genetic or proteomic characteristics and their purpose can be to confirm a diagnosis, serve for epidemiological screening, predict an outcome, monitor disease progression, or assess and predict response to a treatment. In the thorough search for a therapy for PD in the past 30 years, next to the complexity of the disease itself, the lack of reliable tools available to monitor progression and to observe the effects of the interventions has been a major drawback. Screening for biomarkers in PD is therefore highly relevant, but no reliable ones are readily available [110]. To this purpose, the PPMI (Parkinson Progression Marker Initiative) is currently undergoing an observational, multicentre, international study designed to evaluate potential biomarkers of PD progression comprising 400 recently diagnosed PD patients and 200 healthy subjects among a total of 21 centres [111].

Apart from the above-mentioned associated risk factors in PD, specific biomarkers for PD psychosis have to our knowledge not been studied so far; nonetheless biomarkers for cognitive decline, which is a risk factor for the development of psychosis in PD, have been recently published. In a study by Skogseth et al. [112], cerebrospinal fluid (CSF) parameters and cognition in PD were assessed, finding a significant correlation between reduced Alpha-synuclein and reduced composite cognition and executive-attention domain scores. Associations between T-Tau and A-beta42 were not significantly associated with PD-MCI. Alongside this finding, another recent study by Stav et al. showed a significant correlation between A-beta38, A-beta40, and also Alpha-synuclein in PD patients with MCI [113]. In the current literature on biomarkers in cognitive decline in PD, the most consistent finding is an association of reduced A-Beta 42 in CSF, while the findings on T-/P-Tau are inconsistent [114]. With regard to biomarkers for psychosis (in non-PD subjects), a recent study on leukocytic miRNA comparing healthy subjects with persons who were at high risk of psychosis without progressing to psychosis and individuals who did develop psychosis over a course of 2 years showed a specific pattern of expression of small regulatory miRNAs in people who developed psychosis compared to those who did not [115]. They could not find individual miRNAs with statistically significant power; nonetheless a sum of 5 miRNAs was proposed to indicate a progression towards psychosis. This goes along another study by Gardiner et al., in which miRNAs were found to be downregulated in 112 schizophrenia patients when compared to 76 healthy controls [116]. Whether these findings could be extrapolated to PD psychosis remains open and needs further studies.

Along this biochemical biomarkers, imaging studies in schizoid and schizotypal personality disorders have found greater volume loss in the superior part of the corona...
radiata [117] as well as smaller neocortical grey matter volumes with larger sulcal CSF relative volumes [118], as a potential further biomarker of psychotic trails in schizotypal individuals compared to healthy controls. As in the case of the mentioned biochemical biomarkers, further studies are needed with regard to imaging biomarkers as well.

4. Management of PD Psychosis

4.1. Nonpharmacological Treatment. The importance of a multidisciplinary approach for the treatment of PD psychosis has been revised by several authors in the literature and implies the involvement of psychiatrists and other mental health professionals, neurologists, and functional neurosurgeons [119]. With regard to noninterventional treatments, psychoeducation and cognitive behavioural therapy (CBT) have shown efficacy in schizophrenia [120] but have not specifically been assessed in PD psychosis. Active music therapy in PD patients showed benefits in behavioural, as well as in motor and affective functions [121]; however more systematic studies with a higher number of patients are required to study its potential effect as well as its long-term outcome.

4.2. Pharmacological Treatment. It is important to differentiate the treatment strategy of an acute and potentially life-threatening PD psychosis from a chronic setting.

The treatment strategy of acute psychotic episodes in PD is primarily to address and treat the underlying cause, including general measures, treatment of specific triggers, adaptation of medication, and/or addition of cholinesterase inhibitors in cognitively impaired PD patients (rivastigmine, donepezil, or galantamine) and antipsychotic agents such as clozapine or quetiapine when not manageable with the previous steps as shown in Table 5. If there is no response to neuroleptic agents, further investigations such as the measurement of amphetamines, methamphetamine, digoxin, T3, T4, TSH, and protoporphyrin should be considered. A transition from an acute to a chronic state can follow. In the chronic setting of a PD psychosis on the other hand, the first pharmacological approach is the optimization of the administered antiparkinsonian therapy, aiming at the lowest effective dose. The order in which the medication should be reduced is as follows: anticholinergic agents, selegiline, amantadine, dopamine receptor agonists, COMT-inhibitors, and lastly L-Dopa [124]. If reduction of medication however does not improve psychosis, the use of cholinesterase inhibitors or antipsychotic medication similarly as in the treatment strategy of the acute onset PD psychosis needs to be evaluated.

The main antipsychotic drugs used in PD psychosis are clozapine and quetiapine. Clozapine is slightly stronger than quetiapine but has a greater risk to induce agranulocytosis, with an estimated overall prevalence of 1-2% [125].

4.2.1. Clozapine. Clozapine is an atypical antipsychotic whose mechanism of action is only partially understood, being thought to mainly act as an antagonist of dopamine D2 receptors and serotonin 2A receptors. It was first produced in 1958 and sold commercially after 1972. A double-blind, placebo-controlled study on clozapine for the treatment of drug-induced psychosis in PD (PSYCLOPS trial) showed an effectiveness of low-dose clozapine without worsening of motor function and response maintenance over at least 4 months in PD patients with psychosis [126]. A further double-blind, placebo-controlled study by Pollak et al. could find a statistically significant improvement in psychosis scores when compared to placebo, without significant motor function worsening, when using a low dose of clozapine of 50 mg/day. They also found wearing-off of the effect after discontinuation of the therapy [127]. These studies support the effectiveness of low-dose clozapine for the management of psychosis in PD.

4.2.2. Other Antipsychotics. The use of newer antipsychotics was to follow the discovery of clozapine. The beneficial use of atypical antipsychotics in PD has been associated with a statistically significant increased risk of mortality, quetiapine being the weakest one associated with this fatal outcome, as studied in a recent trial by Weintraub et al. [128], so that studies to assess its efficacy in PD psychosis have been sought after.

Quetiapine is a dibenzothiazepine derivative structurally related to clozapine and was approved by the FDA in 1997 [129]. A study by Morgante et al. analyzed in a randomized, rater-blinded trial the effect of clozapine versus quetiapine in 45 PD patients with drug-induced psychosis over 12 weeks and concluded an equally efficacious potential of both drugs with unchanged motor scores among both groups [130]. A further study comparing the two medications by Merims et al. in 27 PD patients with recent-onset psychosis showed similar results but showed an overall trend of clozapine over quetiapine to control hallucinations (P = 0.097) and an advantage in reducing delusions (P = 0.011). Nonetheless the relatively high incidence of agranulocytosis under clozapine therapy poses a limitation in its use and the alternative of using quetiapine remains of importance [131]. Nonetheless, other studies comparing quetiapine to placebo in a total of 31 subjects [132], 58 subjects [133], and 24 subjects [134] failed to show efficacy on hallucinations when comparing quetiapine with placebo.

Studies on olanzapine, another atypical antipsychotic agent with dopamine D2 receptor and serotonin 2A receptor antagonism, could show no significant improvements in drug-induced PD psychosis and significant worsening in motor function in PD patients when compared to placebo in two placebo-controlled trials [135, 136].

Summarising the above-mentioned antipsychotic drugs as shown in Table 6, clozapine is efficacious for the treatment of psychosis in PD with an acceptable risk of side effects, if blood cell count is monitored. For quetiapine there is currently insufficient evidence to conclude on its efficacy for PD psychosis, but its safety profile shows benefit with no need of monitoring. For olanzapine, there is no evidence of efficacy in PD psychosis and an unacceptable motor function deterioration consequently making this compound not recommended for use in PD psychosis.

Less commonly used compounds such as risperidone have shown to be effective in the treatment of PD psychosis, nonetheless worsening motor function [138], so that it is currently not recommended as a treatment for PD psychosis.
Table 5: Proposed treatment strategies of acute, secondary psychosis in Parkinson’s disease.

| Step | Action |
|------|--------|
| I General measures | Reestablishment of circadian rhythms  
Reestablishment of normal-level sensory inputs  
Hearing and vision aids  
Reestablishment of familial environment |
| II Treatment of specific triggers | Treatment of infection, dehydration  
Balancing electrolytes, glucose, vitamins, hormones  
Treatment of heart insufficiency |
| III Elimination of nonessential medication | Particularly anticholinergic, antiglutamatergic, sedating drugs |
| IV Reduction of anti-Parkinson medication | Anticholinergics > amantadine > MAO-B-inhibitors > dopamine agonists > COMT-inhibitors > L-dopa retard > L-dopa nonretarded |
| V Cholinesterase inhibitors in cognitively impaired patients | For example, rivastigmine 6–12 mg/d 2-3/d, or donepezil 5–10 mg/d 1/d (off-label), or galantamine 4–32 mg/d 2-3/d (off-label) |
| VI Antipsychotic medication | Clozapine 12.5–62.5 mg/d (first-line), or quetiapine 12.5–75 mg/d (off-label) |

COMT, catechol-O-methyltransferase; MAO-B, monoamine oxidase B; reference: Levin et al., 2016 [3], taken from Seppi et al., 2011 [122] and Connolly and Lang, 2014 [123].

Table 6: Summary of commonly used antipsychotic drugs to treat PD psychosis.

| Drug   | Efficacy      | Safety                        | Practice Implications |
|--------|---------------|-------------------------------|-----------------------|
| Clozapine | Efficacious   | Acceptable risk with specialized monitoring | Clinically useful |
| Olanzapine | Unlikely efficacious | Unacceptable risk          | Not useful          |
| Quetiapine | Insufficient evidence | Acceptable risk without specialized monitoring | Investigational |

Reference: Seppi et al., 2011 [122].

Ziprasidone has shown to improve PD psychosis symptoms in one small randomized single-blind parallel comparison study between ziprasidone and clozapine in 14 patients by Pintor et al., with no worsening of motor scores or cognitive function when comparing both intervention arms [139]. But to draw clinically relevant conclusions further studies with higher sample sizes are needed. Finally, melperone, another atypical antipsychotic of the butyrophenone chemical class, showed no benefit in the treatment of PD psychosis when compared to placebo in an unpublished double-blind, placebo-controlled trial by Friedman [140].

4.2.3. Pimavanserin. Pimavanserin, a selective 5-HT2A inverse agonist without dopaminergic, adrenergic, histaminergic, or muscarinic effect [141], has been approved by the FDA [142] in September 2014 and has shown to be effective and safe in the treatment of PD psychosis, reducing hallucinations and delusions without affecting motor function [143, 144], which is a commonly observed drawback of most antipsychotic drugs due to dopamine antagonism. Recent studies have shown the potential of this drug to improve psychotic symptoms among PD patients [144, 145]. Results showed a significant improvement in measures of psychosis in PD patients without impairing motor function in one study by Meltzer et al. [145] and a statistically significant decrease in SAPS-PD scores in a bigger cohort of 199 PD patients in a randomized, double-blind, placebo-controlled phase 3 trial by Cummings et al. [144]. But pimavanserin and commonly used antipsychotics have up to now not been systematically compared.

4.2.4. Cholinesterase Inhibitors. Clinical trials to assess the potential benefit of the widely used cholinesterase inhibitors for the treatment of dementia have been studied in PD psychosis due to its close relationship but have shown no beneficial effect on PD psychosis to date [73]. A randomized, placebo-controlled trial of donepezil in cognitive impaired PD patients showed a beneficial effect in memory, with no differences in psychiatric status or motor function [146] and an overall reduced tolerability with the recommendation of careful monitoring when used in PD patients. Another placebo-controlled study of rivastigmine in cognitive impaired PD patients showed moderate improvements in cognitive function but also higher rates of side effects, such as nausea, vomiting, and tremor [106]. Nonetheless, treatment of hallucinations in DLB has been reported to be
Efficacious with cholinesterase inhibitors such as donepezil [147, 148] and a clinical trial on the effect of donepezil in PD psychosis is currently under way [149]. Recommendation to use cholinesterase inhibitors in PD psychosis in cognitively impaired patients is currently supported by some authors [122, 123].

4.3. Electroconvulsive Therapy (ECT) and Deep Brain Stimulation (DBS). Electroconvulsive therapy has shown beneficial effects in the treatment of neuropsychiatric symptoms in PD in some studies in the literature. The most recently published study on the effect of ECT in 29 drug-refractory PD patients with psychiatric symptoms, 12 of them having psychosis and depression and one having isolated psychosis, showed an improvement in measures of motor as well as nonmotor function assessed by means of different scales as seen in Table 7 [137].

This goes along other previous studies on ECT performed on PD patients with psychiatric comorbidities as summarised in Table 8, where most of the studies showed improvements in clinical impression and in the used scales. The mechanism of action of ECT is currently not known; potential postsynaptic dopamine receptor upregulation in the striatum, an increase in postsynaptic dopamine responsiveness, and an increase in levels of L-Dopa in the central nervous system by disrupting the blood-brain-barrier are thought to be underlying [150, 151]. As to its antipsychotic and antidepressant effect, enhancement of serotoninergic neurotransmission and mesocorticolimbic pathway activation has been postulated [152]; a PET study in PD patients with psychosis and depression showed that ECT led to an increase in metabolism in the anterior cingulate cortex and hippocampus, the latter of both showing correlation with a reduction of positive symptoms assessed by the Hamilton Depression Rating Scale (HDRS) [153]. Safety and tolerability issues have not been reported under ECT so far; nonetheless the performed studies to date are only small sample sized, have not been blinded, and have not assessed long-term efficacy. A large, sham-controlled study on the effect of ECT for the treatment of neuropsychiatric symptoms in PD is therefore highly needed. Studies on the effect of ECT in patients with deep brain stimulators have so far not been assessed; an undergoing collection of data to that purpose is under way [154].

Deep brain stimulation (DBS) has been reported as causing psychosis as a potential severe adverse event in PD patients [155], but the direct link to this complication is often overlapped by comorbid conditions and therefore contradictory in the actual literature [155, 156]. Its potential to treat psychiatric disorders in non-PD patients has furthermore shown some promising results in psychiatric conditions such as obsessive compulsive disorders [157]. Nonetheless, current evidence of DBS effect on PD psychosis is scarce and knowledge on its effect, whether improving or worsening the symptoms, cannot be stated at this point of time [19]. A clinical trial for the assessment of DBS for the treatment of resistant schizophrenia is currently under way; whether, if positive, the results could be potentially extrapolated to PD in the future remains open.

5. Conclusion

Although psychosis was thoroughly studied in recent years after being identified as one of the most relevant nonmotor features in PD, standardized guidelines for the management of PD psychosis are not available. Interestingly, psychosis, being one of the hallmarks of psychiatric illnesses such as schizophrenia with patients typically presenting with auditory features [21], presents rather differently in PD patients, where visual hallucinations clearly predominate, implicating a potentially different entity and thus underlying pathophysiological mechanism, further challenging the actual use of the same treatment options for both. In addition, current hypotheses on the underlying pathophysiological mechanisms including neurotransmitter dysregulation, structural/functional brain imaging abnormalities, and blood and CSF based biochemical measurements are sparse and inconsistent, supporting the lack of knowledge and the need of further investigation in order to potentially develop target oriented drugs in the nearer future. Currently undergoing studies on novel drugs for PD psychosis are expected to produce results in due time; ideas of further intervention strategies such as deep brain stimulation or stem cell therapy are being addressed for other causes of psychosis and could, if efficient, pose further options in the future. For now it remains clear that much more effort needs to be put into understanding this condition.
Table 8: Summary of published reports of electroconvulsive therapy for the management of neuropsychiatric symptoms in subjects with Parkinson’s disease.

| Study                | Sample | Neuropsychiatric disorder               | Measurements | Findings                                      |
|----------------------|--------|-----------------------------------------|--------------|-----------------------------------------------|
| Nishioka et al., 2014| 4      | Psychosis                               | NPI HAM-D    | Improvement of 89.8% in the NPI              |
|                      |        |                                         |              | Improvement of 81.1% in the HAM-D            |
| Sadananda et al., 2013| 1      | Psychosis                               | PANNS        | Improvement of 77.3% in the PANNS            |
| Muhammad et al., 2012| 1      | Obsessive-compulsive disorder           | Clinical impression |                              |
| Usui et al., 2011    | 8      | Psychosis                               | SAPS         | Improvement of 65.8% in the mean SAPS total  |
| Ducharme et al., 2011| 1      | Depression                              | Clinical impression |                              |
| Ueda et al., 2010    | 5      | Psychosis                               | BPRS HAM-D   | Improvement of 89.2% in the BPRS             |
| Bailine et al., 2008 | 1      | Psychotic depression                    | Clinical impression |                              |
| Lance et al., 1998   | 1      | Depression                              | Clinical impression |                              |
| Mollentine et al., 1998 | 25     | Depression and/or psychosis, dementia   | BPRS HAM-D   | Improvement                                  |
| Nymeyer et al., 1997 | 1      | Depression                              | Clinical impression |                              |
| Factor et al., 1995  | 2      | Depression and/or psychosis             | Clinical impression |                              |
| Sandky et al., 1993  | 1      | Psychotic depression                    | Clinical impression |                              |
| Oh et al., 1992      | 11     | Depression and/or psychosis             | Clinical impression |                              |
| Zwil et al., 1992    | 8      | Depression and/or psychosis             | Clinical impression |                              |
| Friedman et al., 1992| 5      | Depression and/or psychosis             | Clinical impression |                              |
| Stern, 1991          | 1      | Depression                              | Clinical impression |                              |
| Liberon et al., 1990 | 1      | Psychotic depression                    | Clinical impression |                              |

NPI: neuropsychiatric inventory; HAM-D: Hamilton Depression Rating Scale; PANNS: Positive and Negative Syndrome Scale; SAPS: Scale for the Assessment of Positive Symptoms; BPRS: Brief Psychiatric Rating Scale; reference: Calderón-Fajardo et al., 2015 [157].
Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] J. G. Goldman and S. Holden, “Treatment of psychosis and dementia in Parkinson's disease,” Current Treatment Options in Neurology, vol. 16, no. 3, article 281, 2014.

[2] W.-M. Liu, R.-J. Lin, R.-L. Yu, C.-H. Tai, C.-H. Lin, and R.-M. Wu, “The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 2865–2873, 2015.

[3] J. Levin, A. Hasan, and G. U. Höglinger, “Psychosis in Parkinson's disease: identification, prevention and treatment,” Journal of Neural Transmission, vol. 123, no. 1, pp. 45–50, 2016.

[4] A. Sauerbier, P. Jenner, A. Todorova, and K. R. Chaudhuri, “Non motor subtypes and Parkinson's disease,” Parkinsonism and Related Disorders, vol. 22, pp. 541–546, 2016.

[5] A. Souques, Rapport sur les syndromes parkinsoniens. Revue neurologique, Masson, Paris, France, 1921.

[6] J. De Ajiuraiggera, Ajiuraiggera, Etude psychopathologique des parkinsoniens in Monoamines, noyaux gris centraux et syndromes parkinsoniens, Masson, Paris, France, 1971.

[7] M. Onofri, D. Carrozzino, A. D'Amico et al., “Psychosis in parkinsonism: an unorthodox approach,” Neuropsychiatric Disease and Treatment, vol. 13, pp. 1313–1330, 2017.

[8] J. A. Vilensky, S. Gilman, and S. McCall, “Does the historical literature on encephalitis lethargica support a simple (direct) relationship with postencephalitic Parkinsonism?” Movement Disorders, vol. 25, no. 9, pp. 1124–1130, 2010.

[9] S. A. Factor, E. S. Molho, G. D. Podskalny, and D. Brown, “Parkinson's disease: drug-induced psychiatric states,” Advances in Neurology, vol. 65, pp. 115–138, 1995.

[10] K. A. Josephs, “Capgras syndrome and its relationship to neurodegenerative disease,” Archives of Neurology, vol. 64, no. 12, pp. 1762–1766, 2007.

[11] S. A. Factor and E. S. Molho, “Threatening auditory hallucinations and cotard syndrome in Parkinson disease,” Clinical Neuropsychopharmacology, vol. 27, no. 5, pp. 205–207, 2004.

[12] N. Moschopoulos, S. Kaprinis, and N. Nimatoudis, “Cotard’s syndrome: case report and a brief review of literature,” Psychiatriki, vol. 27, no. 4, pp. 296–302, 2016.

[13] M. Poletti, G. Perugi, C. Logi et al., “Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study,” Movement Disorders, vol. 27, no. 13, pp. 1679–1682, 2012.

[14] D. Georgiev, A. Danieli, L. Ocepek et al., “Othello syndrome in patients with parkinson's disease,” Psychiatria Danubina, vol. 22, no. 1, pp. 94–98, 2010.

[15] World Health Organization, “The ICD-10 Classification of Mental and Behavioural Disorders,” http://www.who.int/classifications/icd/en/GRNBOOK.pdf, 1993.

[16] J. MacK, P. Rabins, K. Anderson et al., “Prevalence of psychotic symptoms in a community-based Parkinson disease sample,” American Journal of Geriatric Psychiatry, vol. 20, no. 2, pp. 123–132, 2012.

[17] J. H. Friedman, “Parkinson disease psychosis: update,” Behavioural Neurology, vol. 27, no. 4, pp. 469–477, 2013.

[18] D. H. Frytche, B. Creese, M. Politis et al., “The psychosis spectrum in Parkinson disease,” Nature Reviews Neurology, vol. 13, no. 2, pp. 81–95, 2017.

[19] D. H. Ffytche, J. B. Pereira, C. Ballard, K. R. Chaudhuri, D. Weintraub, and D. Aarsland, “Risk factors for early psychosis in PD: Insights from the Parkinson’s Progression markers initiative,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 88, no. 4, pp. 325–331, 2017.

[20] B. R. Thanvi, T. C. N. Lo, and D. P. Harsh, “Psychosis in Parkinson's disease,” Postgraduate Medical Journal, vol. 81, no. 960, pp. 644–646, 2005.

[21] S. Chaudhury, “Hallucinations: clinical aspects and management,” Industrial Psychiatry Journal, vol. 19, no. 1, p. 5, 2010.

[22] B. Ravina, K. Marder, H. H. Fernandez et al., “Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH Work Group," Movement Disorders, vol. 22, no. 8, pp. 1061–1068, 2007.

[23] G. Fenelon, “Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms,” CNS Spectrums, vol. 13, no. 3, pp. 18–25, 2008.

[24] J. L. Cummings, “Behavioral complications of drug treatment of Parkinson's disease," Journal of the American Geriatrics Society, vol. 39, no. 7, pp. 708–716, 1991.

[25] D. Weintraub and H. I. Hurtig, “Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies,” American Journal of Psychiatry, vol. 164, no. 10, pp. 1491–1498, 2007.

[26] E. B. Forsaa, J. P. Larsen, T. Wentzel-Larsen et al., “A 12-year population-based study of psychosis in Parkinson disease," Archives of Neurology, vol. 67, no. 8, pp. 996–1001, 2010.

[27] G. Fenelon, F. Mahieux, R. Huon, and M. Ziegler, “Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors," Brain, American Journal of Ophthalmology, vol. 130, no. 2, pp. 261-262, 2000.

[28] C. Pacchetti, R. Manni, R. Zangaglia et al., “Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease," Movement Disorders, vol. 20, no. 11, pp. 1439–1448, 2005.

[29] D. R. Williams, J. D. Warren, and A. J. Lees, “Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism," Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 6, pp. 652–655, 2008.

[30] G. Fenelon, T. Soulsal, F. Zenasni, and L. C. de Langavant, “The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria," Movement Disorders : Official Journal of The Movement Disorder Society, vol. 25, no. 6, pp. 755–759, 2010.

[31] S. Papapetropoulos and D. C. Mash, “Psychotic symptoms in Parkinson's disease: From description to etiology,” Journal of Neurology, vol. 252, no. 7, pp. 753–764, 2005.

[32] S. A. Factor, P. J. Feustel, and J. H. Friedman, “Longitudinal outcome of Parkinson's disease patients with psychosis," Neurology, vol. 60, no. 11, pp. 1756–1761, 2003.

[33] A. Lenka, S. Hegde, K. R. Jhunjhunwala, and P. K. Pal, “Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review," Parkinsonism and Related Disorders, vol. 22, pp. 1–8, 2016.

[34] D. H. Hepp, C. C. da Hora, T. Koene et al., “Cognitive correlates of visual hallucinations in non-demented Parkinson's disease patients," Parkinsonism and Related Disorders, vol. 19, no. 9, pp. 795–799, 2013.
Parkinson's disease," *Biological Psychiatry*, vol. 52, no. 5, pp. 438–445, 2002.

[136] W. G. Ondo, J. K. Levy, K. D. Vuong, C. Hunter, and J. Jankovic, "Olanzapine treatment for dopaminergic-induced hallucinations," *Movement Disorders*, vol. 17, no. 5, pp. 1031–1035, 2002.

[137] H. Calderón-Fajardo, A. Cervantes-Arriaga, R. Llorens-Arenas, J. Ramirez-Bermudez, A. Ruiz-Chow, and M. Rodriguez-Violante, "Electroconvulsive therapy in Parkinson's disease," *Arquivos de Neuro-Psiquiatria*, vol. 73, no. 10, pp. 856–860, 2015.

[138] G. Meco, A. Alessandri, P. Giustini, and V. Bonifati, "Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study," *Movement Disorders*, vol. 12, no. 4, pp. 610–612, 1997.

[139] L. Pintor, F. Valldorriola, E. Baille, M. J. Martí, A. Muñiz, and E. Tolosa, "Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial," *Clinical Neuropharmacology*, vol. 35, no. 2, pp. 61–66, 2012.

[140] J. H. Friedman, "Melperone is ineffective in treating Parkinson's disease psychosis," *Movement Disorders*, vol. 27, no. 6, pp. 803–804, 2012.

[141] N. S. Hunter, K. C. Anderson, and A. Cox, "Pimavanserin," *Drugs of Today*, vol. 51, no. 11, pp. 646–652, 2015.

[142] J. Cummings, S. Isaacson, R. Mills et al., "Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders," *Expert Opinion on Pharmacotherapy*, vol. 9, no. 18, pp. 3251–3259, 2008.

[143] K. E. Vanover, D. M. Weiner, M. Makhay et al., "Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist," *Journal of Pharmacology and Experimental Therapeutics*, vol. 317, no. 2, pp. 910–918, 2006.

[144] A. Abbas and B. L. Roth, "Pimavanserin, a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders," *Expert Opinion on Pharmacotherapy*, vol. 9, no. 18, pp. 3251–3259, 2008.

[145] I. Leroi, J. Brandt, S. G. Reich et al., "Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease," *International Journal of Geriatric Psychiatry*, vol. 19, no. 1, pp. 1–8, 2004.

[146] K. Szigeti and M. U. Hafeez, "Exploring the role of donepezil in Dementia with Lewy Bodies," *Drugs of Today*, vol. 51, no. 10, pp. 579–590, 2015.

[147] J. Cummings, T.-J. Lai, S. Hemrungrojn et al., "Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies," *CNS Neuroscience and Therapeutics*, vol. 22, no. 3, pp. 159–166, 2016.

[148] H. Sawada and T. Oeda, "Protocol for a randomised controlled trial: Efficacy of donepezil against psychosis in Parkinson's disease (EDAP)," *BMJ Open*, vol. 3, no. 9, Article ID e003533, 2013.

[149] D. Popeo and C. H. Kellner, "ECT for Parkinson's disease," *Medical Hypotheses*, vol. 73, no. 4, pp. 468–469, 2009.

[150] R. Kennedy, D. Mittal, and J. O’ílle, "Electroconvulsive Therapy in Movement Disorders: An Update," *Journal of Neuropsychiatry and Clinical Neurosciences*, vol. 15, no. 4, pp. 407–421, 2003.